Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

Cumberland Pharmaceuticals stock opened at $1.74 on Wednesday. Cumberland Pharmaceuticals has a fifty-two week low of $1.55 and a fifty-two week high of $2.91. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.31 and a current ratio of 1.70. The company has a market capitalization of $25.14 million, a P/E ratio of -6.21 and a beta of 0.34. The stock has a 50-day simple moving average of $1.86 and a 200-day simple moving average of $2.20.

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) last posted its earnings results on Tuesday, March 7th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 9.97% and a positive return on equity of 4.76%. The firm had revenue of $9.12 million during the quarter.

Institutional Trading of Cumberland Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC increased its position in Cumberland Pharmaceuticals by 27.8% in the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock valued at $529,000 after acquiring an additional 40,949 shares during the period. Renaissance Technologies LLC increased its position in Cumberland Pharmaceuticals by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 38,100 shares during the period. Millennium Management LLC acquired a new position in Cumberland Pharmaceuticals in the 4th quarter valued at about $46,000. Finally, True Capital Management acquired a new position in Cumberland Pharmaceuticals in the 4th quarter valued at about $27,000. 16.69% of the stock is owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

(Get Rating)

Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex.